News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
SINO BIOPHARM Advances 5%+ at Open, Clarifies Co-op Between LaNova Medicines and Merck & Co. Still Progressing Orderly
SINO BIOPHARM (01177.HK) opened up 5.49% today and once peaked at HKD6.72. It last printed at HKD6.49, up 1.88%, on a volume of 108 million shares, involving HKD705 million.The com...
Reset
Send
The window will close in 5 seconds
SINO BIOPHARM Advances 5%+ at Open, Clarifies Co-op Between LaNova Medicines and Merck & Co. Still Progressing Orderly
Close
Recommend
14
Positive
25
Negative
6
 
 

SINO BIOPHARM (01177.HK)  +0.380 (+5.901%)    Short selling $140.31M; Ratio 13.153%   opened up 5.49% today and once peaked at HKD6.72. It last printed at HKD6.49, up 1.88%, on a volume of 108 million shares, involving HKD705 million.

The company has announced an acquisition of the remaining 95.09% stake in LaNova Medicines to make it its wholly owned subsidiary for a consideration not exceeding USD950 million.

Related NewsM Stanley: SINO BIOPHARM (01177.HK) Transaction Price of LaNova Undemanding
In response to market rumors saying that LaNova Medicines has encountered issues with its licensing collaboration with pharmaceutical giant Merck & Co. on the PD-1/VEGF bispecific antibody LM-299, and that the deal may have been called off, SINO BIOPHARM clarified that their partnership is still proceeding in an orderly manner according to the licensing agreement.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-17 12:25.)

AAStocks Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.